oral glp-1 meds The challenge of developing alternatives to Ozempic, Wegovy and Mounjaro No injections Could a once-a-day pill replace

Chen Y, Li Y, Shen W, Li K, Yu L, Chen Q, et al

The therapeutic window is broad, but optimal dosing balances efficacy against dose-dependent adverse effects

Nagell, C

"We found that fewer than 1 in 4 patients remained on a GLP-1 medication after a year," says Dr

Hydration status: Nausea and reduced oral intake can lead to dehydration, potentially causing acute kidney injury, particularly in older adults

This editorial highlights the long, costly and low-success pathway of CNS drug development, the absence of new psychiatric active substances receiving positive EMA opinions between 2020 and 2024, and persistent underinvestment despite rising clinical burden